Bp2202
Phase 1
Bp2202 is one of 3 therapeutic programs targeting Relapsed Refractory Multiple Myeloma (RRMM). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
2 competitors in Relapsed Refractory Multiple Myeloma (RRMM)
#DrugCompanyPhaseTrials
1Linvoseltamab
RegeneronPreclinical
Bp2202
BBrightPath Biotherapeutics
Phase 1
Regn17372+linvoseltamab
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Bp2202. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- BBrightPath Biotherapeutics